Thrombotic thrombocytopenic purpura temporally associated with BNT162b2 vaccination in an adolescent successfully treated with caplacizumab

Letter Oncology

Refractory acquired thrombotic thrombocytopenic purpura treated with caplacizumab in a pediatric patient with systemic lupus erythematosus

Margaret B. Nagel et al.

PEDIATRIC BLOOD & CANCER (2021)

Review Oncology

Recognizing and managing hereditary and acquired thrombotic thrombocytopenic purpura in infants and children

Anam Siddiqui et al.

Summary: This article describes the presentation, diagnosis, and treatment of infants and children with hereditary and acquired autoimmune thrombotic thrombocytopenic purpura (TTP). Plasma and recombinant ADAMTS13 are effective treatments for exacerbations, while plasma exchange and immunosuppression are common for acquired TTP, with caplacizumab emerging as a potential replacement for plasma exchange.

PEDIATRIC BLOOD & CANCER (2021)

Add to Collection

Article Hematology

Real-world experience with caplacizumab in the management of acute TTP

Tina Dutt et al.

Summary: In a real-world study of 85 patients receiving caplacizumab, it was found that caplacizumab in combination with PEX and other treatments effectively shortened the time to platelet count normalization in a clinical setting, demonstrating favorable outcomes compared to historical controls.

BLOOD (2021)

Add to Collection

Article Hematology

Acquired thrombotic thrombocytopenic purpura: A rare disease associated with BNT162b2 vaccine

Hannah Maayan et al.

Summary: This study presents a case series of patients who developed acquired Thrombotic Thrombocytopenic Purpura shortly after receiving the BNT162b2 vaccine. It recommends evaluating ADAMTS13 activity in patients with a history of aTTP before and after vaccination, especially with the SARS-CoV-2 vaccine. Close monitoring of patients' clinical situation and laboratory data post-vaccination is essential.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)

Add to Collection

Article Hematology

First report of a de novo iTTP episode associated with an mRNA-based anti-COVID-19 vaccination

Severine de Bruijn et al.

Summary: This case report describes a 38-year-old woman who developed de novo iTTP after receiving an mRNA-based COVID-19 vaccine. She presented with skin bruising and petechiae 2 weeks after vaccination. Treatment with plasma exchange, corticosteroids, rituximab, and caplacizumab was successful in managing her condition.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)

Add to Collection

Article Hematology